Add 2 More Reports For 20% off

Report Overview

According to the American Cancer Society, in 2024, over 600,000 individuals in the United States are expected to die from cancer. As a result, the emphasis on developing high-efficacy therapies for treatment is at its peak. With collaborations between biotech companies, research and academic institutions, oncolytic virus therapies are witnessing accelerated development and commercialization.

Key Takeaways

  • Continuous progress in clinical trials along with approvals from regulatory authorities like the United States FDA are boosting the market growth for oncolytic virus cancer therapies.
  • Technical advancements in delivery systems, and virus engineering leading to enhanced efficacy of oncolytic virus therapies is among major market trends.
  • Some of the oncolytic virus cancer therapy pipeline drugs currently in the oncolytic virus cancer drugs pipeline include CF33-hNIS, R130, LOAd703 and OH2, among others.

Report Coverage

The Oncolytic Virus Cancer Therapy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into oncolytic virus cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for oncolytic virus cancer therapy. The oncolytic virus cancer therapy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The oncolytic virus cancer therapy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with oncolytic virus cancer therapy treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to oncolytic virus cancer therapy.

Oncolytic Virus Cancer Therapy Pipeline Outlook

Oncolytic virus cancer therapy involves the administration of a virus to attack the tumor cells in a cancer patient's body. These cancer cells infecting virus cells replicate at a fast pace and destroy tumor cells by opening their exterior and exposing the cell content to the immune system.

Only one oncolytic virus, T-VEC (talimogene laherparepvec) has been approved by the United States FDA for metastatic melanoma. Approved in 2015, T-VEC (Imlygic®) is a modified version of herpes simplex virus (HSV). It has been modified to infect cancer cells to produce GM-CSF (an immune-stimulating protein).

These viruses are designed in a way to target cancer cells by identifying their abnormalities such as mutations or differences on the cell surface of proteins. The study of oncolytic therapies is based on several virus types such as adenoviruses, herpes simplex viruses, poxviruses, and others. Each type of virus has a unique characteristic that influences its safety and efficacy against a distinct type of cancer cell. Several oncolytic virus cancer therapy drugs are currently under clinical trials.

The Oncolytic Virus Cancer Therapy Pipeline Report covers the pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.

Oncolytic Virus Cancer Therapy Pipeline Therapeutic Assessment

This section of the report covers the analysis of oncolytic virus cancer therapies drug candidates on various segmentations such as:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Route of Administration

EMR’s oncolytic virus cancer therapy report assessment report covers 50+ drug analyses based on the route of administration.

  • Oral
  • Parenteral
  • Others

Oncolytic Virus Cancer Therapy – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I trials cover a major share of the total clinical trials conducted, with approximately 40 plus oncolytic virus cancer therapy emerging drugs undergoing clinical development.

Oncolytic Virus Cancer Therapy – Pipeline Assessment Segmentation, By Route of Administration

The route of administration categories covered under the oncolytic virus cancer therapy pipeline analysis include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to EMR analysis, the parenteral route holds a significant market share based on the route of administration.

Oncolytic Virus Cancer Therapy Clinical Trials Assessment – Competitive Dynamics

The EMR report for the oncolytic virus cancer therapy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed oncolytic virus cancer therapy clinical assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in oncolytic virus cancer therapy clinical trials:

  • Oncostar LLC
  • Lokon Pharma AB
  • Binhui Biopharmaceutical Co., Ltd.
  • Hangzhou Converd Co., Ltd.
  • Syneos Health, Inc.
  • Astellas Pharma Global Development, Inc.
  • Johnson & Johnson Enterprise Innovation Inc.

Oncolytic Virus Cancer Therapy – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs. It covers product description, trial ID, study type, drug class, mode of administration, and recruitment status of oncolytic virus cancer therapy clinical trial drugs.

CF33-hNIS

It is an oncolytic virus monotherapy candidate that is being investigated for gastrointestinal cancer treatment by a team of researchers at the Karmanos Cancer Center in Detroit, United States. CF33-hNIS has started demonstrating evidential efficacy against the condition.

R130

This oncolytic virus injection is being evaluated for advanced solid tumor treatment. Sponsored by Shanghai Yunying Medical Technology, this recombinant oncolytic herpes simplex virus type 1 (R130) is under investigation against breast cancer and pancreatic cancer.

LOAd703

An oncolytic adenovirus, LOAd703 is an oncolytic virus cancer therapy drug candidate. As a part of the study, it will be administered via intramural injections and will be added to standard-of-care treatment with gemcitabine and nab-paclitaxel.

OH2

Developed by making genetic alterations in the herpes simplex virus type 2 strain HG52, OH2 oncolytic cancer is under trials for locally advanced or metastatic bladder cancer. Currently evaluated in the BH-OH2-017 multicenter clinical trial, it will be delivered once every two weeks. However, the injection dosage will be reduced to once a month during the maintenance treatment period.

Reasons To Buy This Report

The Oncolytic Virus Cancer Therapy Drug Report provides a strategic overview of the latest and future landscape of treatments for oncolytic virus cancer therapy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the oncolytic virus cancer therapy pipeline insights.

Key Questions Answered in the Oncolytic Virus Cancer Therapy – Pipeline Assessment Report

  • What is the current landscape of oncolytic virus cancer therapy drugs?
  • How many companies are developing oncolytic virus cancer therapies?
  • How many phase I and phase II drugs are currently present in oncolytic virus cancer therapies?
  • Which companies/institutions are leading the oncolytic virus cancer therapy development?
  • What is the efficacy and safety profiles of oncolytic virus cancer therapy?
  • What are the opportunities and challenges present in the oncolytic virus cancer therapy landscape?
  • Which company is conducting major trials for oncolytic virus cancer therapy?
  • What are the geographies covered for clinical trials in oncolytic virus cancer therapy?
  • What are emerging trends in oncolytic virus cancer therapy clinical trials?

Related Reports

Cancer Screening Market

Cancer Therapeutics Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report Details
Drug Pipeline by Clinical Trial Phase
  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products 
Route of Administration
  • Oral
  • Parenteral
  • Others
Drug Classes
  • Small Molecule
  • Polymer
  • Monoclonal Antibody
  • Peptides
  • Gene Therapy
Treatment Type
  • Chemotherapy
  • Immunotherapy
  • Hormone Therapy
  • Targeted Therapy
  • Others
Leading Sponsors Covered
  • Oncostar LLC 
  • Lokon Pharma AB 
  • Binhui Biopharmaceutical Co., Ltd. 
  • Hangzhou Converd Co., Ltd. 
  • Syneos Health, Inc. 
  • Astellas Pharma Global Development, Inc. 
  • Johnson & Johnson Enterprise Innovation Inc. 
Geographies Covered
  • North America
  • Europe
  • Asia Pacific
  • Others

Purchase Full Report

Datasheet

 

USD 2,199

USD 1,899

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 2,749

USD 2,299

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 3,849

USD 3,299

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 4,949

USD 4,199

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124